Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2024 | Assessing treatment options for lung cancer with interstitial lung disease

Matthew Hatton, MBChB, MSc, FRCP, FRCR, University of Sheffield, Sheffield, UK, emphasizes the importance of careful patient assessment when considering treatment options for lung cancer with interstitial lung disease (ILD). He underscores the need to evaluate both the cancer itself and the patient’s overall health to determine if potentially curative treatments are viable. However, he acknowledges that treatments such as surgery and radiotherapy pose higher risks for these patients due to their underlying ILD. Therefore, treatment decisions must be made by considering the balance between potential benefits and risks, with active involvement from the patient in the decision-making process. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.